Study Completed

Urinary Tract Infections

Bayer Identifier:

100534

ClinicalTrials.gov Identifier:

NCT00663806

EudraCT Number:

Not Available

EU CT Number:

Not Available

A Phase IV study of Cipro XR in uncomplicated UTI

Trial purpose

Safety and efficacy of Cipro XR in a naturalistic setting and the effectiveness of an educational brochure. - Women with urinary tract infections were treated with Cipro XR. They were also given a brochure with information about urinary tract infections and later tested on the information.

Key Participants Requirements

Sex

Female

Age

18 - 65 Years

Inclusion Criteria
- Ambulatory women outpatients 18 to 65 years of age with a documented clinical diagnosis of uUTI characterized by dysuria with either urgency or frequency. Women of childbearing age were enrolled only if they were highly unlikely to conceive during the study and were practicing a suitable method of birth control or were at least 1 year postmenopausal.
- Positive leukocyte esterase (>/= 1+) and positive nitrite test using a urine dipstick method of analysis.
- Willing to give written consent.
Exclusion Criteria
- Pregnant or nursing
- Complicated UTI
- Allergy to Cipro XR

Trial summary

Enrollment Goal

7614

Trial Dates

February 2003 - July 2003

Phase

Phase 4

Could I Receive a placebo

Products

Cipro XR (Ciprofloxacin, BAYQ3939)

Accepts Healthy Volunteer

Primary Outcome

To compare the effect on knowledge of uncomplicated urinary tract infection (uUTI) in patients who were given a disease-directed educational brochure to read versus patients who were not given the brochure.
Time Frame:
3-10 days after start of therapy
Safety Issue:
no

Secondary Outcome

To examine the difference between physician and patient perceptions of the symptoms of uUTI.
Time Frame:
At baseline visit pre-therapy
Safety Issue:
no
To collect data on the clinical efficacy and safety of Cipro XR, 500 mg, PO once daily, for 3 days, in the treatment of uUTI in a naturalistic setting.
Time Frame:
1-3 days after end of therapy for efficacy and up to 30 days for safety
Safety Issue:
yes

Trial design

EXPRESS: Evaluating Cipro XR Patient Response, Education, Safety, and Satisfaction

Trial Type

Interventional

Intervention Type

Behavioral

Trial Purpose

Other

Allocation

Randomized

Blinding

Open Label

Assignment

Parallel Assignment

Trial Arms

Additional Information

Click here and search for drug information provided by the FDA.Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.Click here to find results for studies related to Bayer Healthcare products.